(Q35196601)

7 August 2017

1 reference

title

Virally targeted therapies for EBV-associated malignancies (English)

1 reference

7 August 2017

Bruce F Israel

1

1 reference

7 August 2017

Shannon C Kenney

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

22

1 reference

7 August 2017

issue

33

1 reference

7 August 2017

page(s)

5122-5130

1 reference

Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Promoter sequences required for reactivation of Epstein-Barr virus from latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Detection of Epstein-Barr virus in invasive breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Use of EBV-Based Vector/HVJ-Liposome Complex Vector for Targeted Gene Therapy of EBV-Associated Neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Histone acetylation and reactivation of Epstein-Barr virus from latency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Phosphoinositide 3-kinase induces the transcriptional activity of MEF2 proteins during muscle differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

Regulation of the BZLF1 promoter of Epstein-Barr virus by second messengers in anti-immunoglobulin-treated B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Calcium modulation activates Epstein-Barr virus genome in latently infected cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Stress-induced immediate-early gene, egr-1, involves activation of p38/JNK1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

YY1 binds to and regulates cis-acting negative elements in the Epstein-Barr virus BZLF1 promoter

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Adaptive radiation in a heterogeneous environment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Characterization of proteins binding to the ZII element in the Epstein-Barr virus BZLF1 promoter: transactivation by ATF1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

The cellular YY1 transcription factor binds a cis-acting, negatively regulating element in the Epstein-Barr virus BRLF1 promoter.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Persisting oncogenic herpesvirus induced by the tumour promoter TPA

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1206548

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1206548

1 reference

Dimensions Publication ID

7 August 2017

1040757147

0 references

1 reference